SK bioscience Co.,Ltd. Statistics
Want to see KR:302440 full AI Analyst Report?
SK bioscience Co.,Ltd. (302440) Stock Statistics & Valuation Metrics
Total Valuation
SK bioscience Co.,Ltd. has a market cap or net worth of KRW 3.08T. The enterprise value is KRW 2.77T.
- Market Cap
- KRW 3.08T
- Enterprise Value
- KRW 2.77T
Share Statistics
SK bioscience Co.,Ltd. has 78,456,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 78,456,550
- Owned by Insiders
- ―
- Owned by Institutions
- 3.07%
Financial Efficiency
SK bioscience Co.,Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -3.75%.
- Return on Equity (ROE)
- -0.03
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -3.75%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 661.96M
- Profits Per Employee
- -57.09M
- Employee Count
- 984
- Asset Turnover
- 0.22
- Inventory Turnover
- 3.13
Valuation Ratios
The current PE Ratio of SK bioscience Co.,Ltd. is -31.57. SK bioscience Co.,Ltd.’s PEG ratio is 0.07.
- PE Ratio
- -31.57
- PS Ratio
- 4.46
- PB Ratio
- 2.07
- Price to FCF
- -24.32
- Price to Operating Cash Flow
- -131.02
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, SK bioscience Co.,Ltd. had revenue of 651.37B and earned -56.17B in profits. Earnings per share was -718.26.
- Revenue
- 651.37B
- Gross Profit
- 59.49B
- Operating Income
- -151.33B
- Pretax Income
- -85.86B
- Net Income
- -56.17B
- EBITDA
- -60.31B
- Earnings Per Share (EPS)
- -718.26
Cash Flow
In the last 12 months, operating cash flow was -26.83B and capital expenditures -99.97B, giving a free cash flow of -126.80B billion.
- Operating Cash Flow
- -26.83B
- Free Cash Flow
- -126.80B
- Free Cash Flow per Share
- -1417.75
Dividends & Yields
SK bioscience Co.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.11%
- Earnings Yield
- -2.61%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- -28.02%
- 50-Day Moving Average
- 36144.00
- 200-Day Moving Average
- 39595.75
- Relative Strength Index (RSI)
- 63.43
- Average Volume (3m)
- 87.67K
Important Dates
SK bioscience Co.,Ltd. upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
SK bioscience Co.,Ltd. as a current ratio of 3.82, with Debt / Equity ratio of 26.27%
- Current Ratio
- 3.82
- Quick Ratio
- 3.24
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -6.04
- Interest Coverage Ratio
- -16.10
Taxes
In the past 12 months, SK bioscience Co.,Ltd. has paid -29.69B in taxes.
- Income Tax
- -29.69B
- Effective Tax Rate
- 0.35
Enterprise Valuation
SK bioscience Co.,Ltd. EV to EBITDA ratio is -27.08, with an EV/FCF ratio of -28.14.
- EV to Sales
- 5.16
- EV to EBITDA
- -27.08
- EV to Free Cash Flow
- -28.14
- EV to Operating Cash Flow
- -132.99
Balance Sheet
SK bioscience Co.,Ltd. has KRW 832.55B in cash and marketable securities with KRW 558.63B in debt, giving a net cash position of KRW 273.92B billion.
- Cash & Marketable Securities
- KRW 832.55B
- Total Debt
- KRW 558.63B
- Net Cash
- KRW 273.92B
- Net Cash Per Share
- KRW 3,491.40
- Tangible Book Value Per Share
- KRW 18.49K
Margins
Gross margin is 10.95%, with operating margin of -22.70%, and net profit margin of -13.29%.
- Gross Margin
- 10.95%
- Operating Margin
- -22.70%
- Pretax Margin
- -11.51%
- Net Profit Margin
- -13.29%
- EBITDA Margin
- -19.07%
- EBIT Margin
- -33.35%
Analyst Forecast
The average price target for SK bioscience Co.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 10.72%
- EPS Growth Forecast
- -1481.30%
Scores
- Smart Score
- ―
- AI Score
- 50

